* Vivos Therapeutics Inc VVOS.OQ reported a quarterly
adjusted
loss of $3.05 per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-5.00. The mean expectation of two analysts
for the quarter was for a loss of $1.90 per share. Wall Street
expected results to range from $-2.06 to $-1.75 per share.
* Revenue fell 17.8% to $3.25 million from a year ago;
analysts
expected $3.41 million.
* Vivos Therapeutics Inc's reported EPS for the quarter was
a loss
of $3.05.
* The company reported a quarterly loss of $4.26 million.
* Vivos Therapeutics Inc shares had fallen by 62.6% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 7.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $7.13
This summary was machine generated from LSEG data March 28 at
09:37 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -1.90 -3.05 Missed
Sep. 30 2023 -3.12 -1.62 Beat
Jun. 30 2023 -3.62 -4.50 Missed
Mar. 31 2023 -4.50 -1.75 Beat